Abstract
The case of a female patient with acute lymphoblastic leukaemia and chronic disseminated candidiasis, who was refractory to 1.8 g conventional amphotericin B therapy, is reported. She experienced severe amphotericin-B-related side-effects in spite of pretreatment, but was subsequently successfully treated with 3 g of a small unilamellar liposome formulation of amphotericin B prepared from soya phosphatidylcholine and cholesterol in a 7∶3 molar ratio at our institute. The patient experienced minimal side-effects with this preparation, although no pretreatment was given. Liposomal amphotericin B prepared in our institute appears to be a safe and effective therapy for systemic fungal infections. However, large controlled studies are required to determine more precisely the potential of liposomal amphotericin B in the treatment of severe systemic fungal infection.
Key words: Acute lymphoblastic leukaemia, Chronic disseminated candidiasis, Amphotericin B, Small unilamellar liposomes
References
- Bodey GP (1984) Candidiasis in cancer patients. Am J Med 77:13–19 [PubMed] [Google Scholar]
- Gokhale PC, Kotwani RN, Dange SY, Kshirsagar NA, Pandya SK (1993) Preclinical and pharmaceutical testing of liposomal amphotericin B. Ind J Med Res 98:75–79 [PubMed] [Google Scholar]
- Gokhale PC, Barapatre RJ, Advani SH, Kshirsagar NA, Pandya SK (1993) Pharmacokinetics and tolerability of liposomal amphotericin B in patients. J Antimicrob Chemother (in press) [DOI] [PubMed]
- Haron E, Feld R, Ruffnell P, Patterson B, Hasselback R, Matlow A (1987) Hepatic candidiasis: an increasing problem in immunocompromised patients. Am J Med 83:17–26 [DOI] [PubMed] [Google Scholar]
- Hawkins C, Armstrong D (1984) Fungal infections in the immunocompromised host. Clin Haematol 13:599–630 [PubMed] [Google Scholar]
- Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano RL, Bodey GP (1985) Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 151:704–710 [DOI] [PubMed] [Google Scholar]
- Maddux MS, Barriere SL (1980) A review of complications and amphotericin B therapy: recommendations for prevention and management. Drug Intel Clin Pharm 14:177–181 [Google Scholar]
- Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Fenaux P, Prentice HG, Ksionski G (1991) Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 28 [Suppl B]:73–82 [DOI] [PubMed] [Google Scholar]
- Sculier JP, Coune A, Meunier F, Brassinne C, Laduron C, Hollaert C, Collette N, Heymans C, Klastersky J (1988) Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 24:527–538 [DOI] [PubMed] [Google Scholar]
- Shirkhoda A, Lopez-Berestein G, Holbert JM, Luna MA (1986) Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B. Radiology 9:349–353 [DOI] [PubMed] [Google Scholar]